QUARTERLY REPORT FOR SMALL BUSINESS ISSUERS SUBJECT
                     TO THE 1934 ACT REPORTING REQUIREMENTS

                     U.S. SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB

(Mark One)

[X]    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE  SECURITIES
       EXCHANGE ACT OF 1934

                  For the quarterly period ended  June 30, 2003
                  ---------------------------------------------

[ ]    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
       SECURITIES EXCHANGE ACT OF 1934

For the transition period from            to
                               ----------    ----------

Commission file number
                        --------------------------

                           Axiom Pharmaceuticals, Inc
                           --------------------------
              (Exact name of small business issuer in its charter)


             Nevada                                          75-2853946
    ------------------------------                       --------------------
   (State or other jurisdiction of                       (I.R.S. Employer
    incorporation or organization)                        Identification No.)


US Representative Office
8324 Delgany Avenue, Playa del Rey, CA 90293                    10036
--------------------------------------------                  --------
 (Address of principal executive offices)                    (Zip Code)

Issuer's telephone number    (310) 301-7728

         Check whether the issuer (1) has filed all reports required to be filed
by  Section  13 or 15(d)  of the  Securities  Exchange  Act of 1934  during  the
preceding  twelve  months (or for such shorter  period that the  registrant  was
required  to file  such  reports),  and  (2) has  been  subject  to such  filing
requirements for the past 90 days.

Yes X .  No   .
   ---     ---


         APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
         PROCEEDINGS DURING THE PRECEDING FIVE YEARS

         Check whether the registrant  filed all documents and reports  required
to be  filed  by  Section  12,  13,  or  15(d) of the  Exchange  Act  after  the
distribution of securities under a plan confirmed by a court.  Yes     No
                                                                   ---    ---

         APPLICABLE ONLY TO CORPORATE ISSUERS

State the number of shares  outstanding  of each of the issuer's class of common
equity,  as of the last practicable  date: As of August 12, 2003 the Company had
13,186,680   shares  of  voting  Common  Stock,   $.001  par  value  issued  and
outstanding.

         Transitional Small Business Disclosure Format (check one):
                                                                    ----   ----


<PAGE>

<TABLE>

<CAPTION>


                         PART I - FINANCIAL INFORMATION

ITEM I.  FINANCIAL STATEMENTS

                           AXIOM PHARMACEUTICALS, INC.
                           CONSOLIDATED BALANCE SHEET
                                  JUNE 30, 2003
                                   (UNAUDITED)

                                             ASSETS
<S>                                                                                   <C>

Current assets
  Cash                                                                                $           22,355
  Cash held in trust by related party                                                            141,129
  Accounts receivable, net of allowance of $0                                                  1,577,052
  Inventories                                                                                  2,246,497
                                                                                      ------------------
    Total current assets                                                                       3,987,033

Property and equipment, net                                                                       78,385
Licenses                                                                                       1,449,748
                                                                                      ------------------

    TOTAL ASSETS                                                                      $        5,515,166
                                                                                      ==================

                              LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities
  Value added tax payable                                                             $        1,764,735
  Accounts payable and accrued expenses                                                          413,753
                                                                                      ------------------
    Total current liabilities                                                                  2,178,488
                                                                                      ------------------

STOCKHOLDERS' EQUITY:
  Preferred stock, $.001 par value, 10,000,000 shares authorized,
    no shares issued and outstanding                                                                   -
  Common stock, $.001 par value, 50,000,000 shares authorized,
    13,186,680 shares issued and outstanding                                                      13,187
  Additional paid-in capital                                                                   5,250,748
  Accumulated deficit                                                                         (1,962,604)
  Accumulated other comprehensive income                                                          35,347
                                                                                      ------------------
    Total Stockholders' Equity                                                                 3,336,678
                                                                                      ------------------

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY                                            $        5,515,166
                                                                                      ==================
</TABLE>


<PAGE>

<TABLE>

<CAPTION>


                           AXIOM PHARMACEUTICALS, INC.
                      CONSOLIDATED STATEMENTS OF OPERATIONS
                THREE AND SIX MONTHS ENDED JUNE 30, 2003 AND 2002
                                   (UNAUDITED)


                                           Three Months Ended                          Six Months Ended
                                                June 30,                                   June 30,
                                -----------------------------------------  -----------------------------------------
                                       2003                 2002                  2003                  2002
                                -------------------  --------------------  --------------------  -------------------
<S>                             <C>                  <C>                   <C>                   <C>

          Revenues              $        1,848,057   $          970,374    $        3,215,216    $        1,578,104

  Cost of revenues                       1,037,365              652,974             1,964,774               976,104
                                ------------------   ------------------    ------------------    ------------------

      Gross profit                         810,692              317,400             1,250,442               602,000
                                ------------------   ------------------    ------------------    ------------------

General, administrative
       and selling                         488,069              199,758               855,529               296,898

Non-cash consulting
       expenses                            787,500                    -               787,500                     -
                                ------------------   ------------------    ------------------    ------------------

                                         1,275,569              199,758             1,643,029               296,898
                                ------------------   ------------------    ------------------    ------------------

 Net income (loss)              $         (464,877)  $          117,642    $         (392,587)   $          305,102
                                ==================   ==================    ==================    ==================

Net income (loss) per
 share:                         $                    $                     $                     $
    Basic and diluted                      (0.04)                0.01                 (0.03)                 0.03
                                ==================   ==================    ==================    ==================
Weighted averaged shares
      outstanding:
    Basic and diluted                   13,010,636           11,420,000            12,984,828            11,420,000
                                ==================   ==================    ==================    ==================
</TABLE>








<PAGE>

<TABLE>

<CAPTION>

                           AXIOM PHARMACEUTICALS, INC.
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                     SIX MONTHS ENDED JUNE 30, 2003 AND 2002
                                   (UNAUDITED)

                                                                               2003                  2002
                                                                         ------------------    ------------------
<S>                                                                      <C>                   <C>

CASH FLOWS FROM OPERATING ACTIVITIES
  Net income (loss)                                                      $        (392,587)    $         305,102
  Adjustments to reconcile net loss to cash used in
    operating activities:
      Common stock issued for services                                             787,500                     -
      Depreciation and amortization                                                 32,796                 9,782
        Changes in assets and liabilities:
          Cash held in trust                                                         8,074               887,563
          Accounts receivable                                                     (644,051)             (687,844)
          Advances                                                                 291,597              (556,082)
          Inventories                                                             (921,573)             (141,934)
          Accounts payable                                                         (12,230)                    -
          Value added tax payable                                                  552,664               334,227
          Accrued expenses                                                         205,857               (46,894)
                                                                         -----------------     -----------------
CASH FLOWS PROVIDED BY (USED IN)
  OPERATING ACTIVITIES                                                             (91,953)              103,920
                                                                         -----------------     -----------------

CASH FLOWS FROM INVESTING ACTIVITIES
  Capital expenditures                                                             (27,235)                    -
  Cash received in reverse merger                                                      169                     -
                                                                         -----------------     -----------------

CASH FLOWS FROM INVESTING ACTIVITIES                                               (27,066)                    -
                                                                         -----------------     -----------------

Effect of exchange rate changes on cash                                             35,347                     -
                                                                         -----------------     -----------------

NET INCREASE (DECREASE) IN CASH                                                    (83,672)              103,920

Cash, beginning of period                                                          106,027                     -
                                                                         -----------------     -----------------

Cash, end of period                                                      $          22,355     $         103,920
                                                                         =================     =================

SUPPLEMENTAL NON-CASH TRANSACTIONS:
  Net liabilities assumed in reverse merger                              $          22,692     $               -
  Assets acquired for common stock                                       $          26,250     $               -
</TABLE>



<PAGE>




                           AXIOM PHARMACEUTICALS, INC.

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                   (Unaudited)

                   For the period ended June 30,2003 and 2002

NOTE 1: MANAGEMENT REPRESENTATION AND PRESENTATION

The  financial   statements   included   herein  have  been  prepared  by  Axiom
Pharmaceuticals,  Inc. ("the Company"), without audit, pursuant to the rules and
regulations  of the  Securities  and Exchange  Commission.  Certain  information
normally  included  in the  financial  statements  prepared in  accordance  with
accounting  principles  generally  accepted in the United  States of America has
been  omitted  pursuant  to such rules and  regulations.  However,  the  Company
believes that the disclosures are adequate to make the information presented not
misleading.

The  balance  sheet of Axiom  Pharmaceuticals,  Inc.  as of June 30,  2003,  the
related consolidated statements of operations for the three and six months ended
June 30, 2003 and 2002 and the consolidated statements of cash flows for the six
months  ended June 30,  2003 and 2002  included  in the  consolidated  financial
statements  have been prepared by the Company  without audit.  In the opinion of
management,  the  accompanying  consolidated  financial  statements  include all
adjustments (consisting of normal, recurring adjustments) necessary to summarize
fairly Axiom's  consolidated  financial position and results of operations.  The
consolidated  results of operations  for the three and six months ended June 30,
2003 are not  necessarily  indicative of the results of operations  for the full
year or any other interim period.  Notes to the financial statements which would
substantially  duplicate  the  disclosure  contained  in the  audited  financial
statements  for the most  recent  fiscal  year  ended  December  31,  2002 to be
reported in Form 8-K/A, have been omitted.


NOTE 2: COMMON STOCK

During the six months  ending June 30,  2003,  Axiom  issued  325,000  shares of
common stock for services  valued at $787,500 and issued 15,000 shares of common
stock for the development of a web site for $26,250.


NOTE 3: CONSULTING FEE CONTINGENT ON FINANCING

Axiom is a party to a consulting  agreement that  provides,  inter alia, for the
payment by Axiom to the consultant of a fee of $145,000. This fee, however, only
becomes due and payable upon the closing by Axiom of a debt or equity  financing
of at least $1,000,000.  The term of the consulting  agreement is for 1 year and
expires in July 2003,  although the compensation terms survive expiration of the
term of the agreement.



<PAGE>


ITEM 2.  MANANGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS

The  following  discussion  should  be read in  conjunction  with our  Financial
Statements  and Notes  thereto  which  appear  elsewhere in this  document.  The
results  shown  herein  are not  necessarily  indicative  of the  results  to be
expected  in  any  future  periods.  This  discussion  contains  forward-looking
statements based on current expectations,  which involve  uncertainties.  Actual
results   and  the  timing  of  events   could   differ   materially   from  the
forward-looking  statements as a result of a number of factors.  Readers  should
also  carefully  review  factors set forth in other reports or documents that we
file from time to time with the Securities and Exchange Commission.

Overview

On March 14, 2003, we completed a Share  Exchange  (the "Share  Exchange ") with
Werke Pharmaceuticals,  Inc. ("Werke"), a Delaware corporation formed to develop
and finance the growth of Chinese based pharmaceutical companies. As a result of
the Share  Exchange,  Werke became our wholly owned  subsidiary.  Werke's wholly
owned operating  subsidiary is Shenyang  Tianwei Werke  Pharmaceutical  Co. Ltd.
("STWP),  a  northern  China-based1   pharmaceutical  company.  The  comparables
discussed  below  relate  to the  operations  of  Werke  and  its  wholly  owned
subsidiary, STWP, for the periods discussed.

We anticipate seeking Chinese government  approval to repackage our product line
with the Axiom  Pharmaceutical  brand during the third quarter of 2003 following
completion  of a  full  redesign  and  reconfiguration  of our  products  by our
international  brand consulting firm and the initiation of the construction of a
new manufacturing and distribution facility in Shenyang, China.

Our  products  are  currently   primarily  sold  through   several  third  party
distributors to hospital pharmacies in the key cities of Shanghai, Guangzhou and
Shenyang.  We anticipate expanding our sales into retail pharmacies within these
regions  during the next quarter and will make  efforts to expand both  hospital
and retail pharmacy sales into other regional cities such as Beijing.

We  are  currently   seeking  to  license  various  branded  OTC  products  from
identifiable  North  American   pharmaceutical  and  supplement   companies  for
distribution and manufacturing in China and Asia-Pacific.

COMPARISON OF RESULTS FOR THE FISCAL  QUARTER ENDED JUNE 30, 2003, TO THE FISCAL
QUARTER  ENDED JUNE 30, 2002 AND THE SIX MONTHS ENDED JUNE 30, 2003,  TO THE SIX
MONTHS ENDED JUNE 30, 2002.



-----------------------
1 All  references  to "China"  herein refer to the  People's  Republic of China,
unless otherwise indicated.


<PAGE>


REVENUE.  During the  three-month  period  ended  June 30,  2003,  we  generated
$1,848,057  from product  sales  compared to revenues from product sales for the
three-month  period  ended June 30, 2002,  of  $970,374.  This is an increase of
$877,683  or 90.5 %.  During  the  six-month  period  ended  June 30,  2003,  we
generated  $3,215,216 from product sales compared to revenues from product sales
for the six-month period ended June 30, 2002, of $1,578,104. This is an increase
of  $1,637,112  or 103.7%.  Revenues  were higher in the 2003  periods due to an
improved and streamlined OEM manufacturing  process and more robust sales of our
product line, particularly the sale of Asarone.

GROSS  PROFIT.  Gross profit on product sales for the  three-month  period ended
June 30, 2003,  was $810,692  compared to $317,400  for the  three-month  period
ended June 30, 2002, an increase of $493,292 or 155.4%.  Gross profit on product
sales for the six-month  period ended June 30, 2003, was $1,250,442  compared to
$602,000 for the  six-month  period ended June 30, 2002, an increase of $648,442
or 107.7%.  The increase in gross profits during the  three-month  and six-month
periods  ended June 30, 2003,  was due  primarily  due to an increase in Asarone
sales and more efficient third party product manufacturing.

SALES,   GENERAL  AND   ADMINISTRATIVE   EXPENSES.   We  incurred   General  and
Administrative  expenses of $488,069 for the  three-month  period ended June 30,
2003,  compared to $199,758 for the  three-month  period ended June 30, 2002, an
increase of $288,311 or 144.3%. During the six month period ended June 30, 2003,
we incurred General and Administrative expenses of $855,529 compared to $296,898
for the six-month period ended June 30, 2002, an increase of $558,631 or 188.1%.
The increases in General and Administrative  expenses during the three-month and
six-month periods ended June 30, 2003, as compared to the comparable periods for
2002, were a result of increased  expenses  related selling and marketing of our
products;  expenses  associated with our public reporting status;  and increased
activities associated with the proposed construction of a new plant in Shenyang.

NON-CASH  CONSULTING  ACTIVITIES.  During the three-month  period ended June 30,
2003,  our Board of Directors  authorized  the issuance of 340,000 shares of our
restricted common stock to various  consultants in lieu of cash payments.  Based
upon the common stock trading price at the times of issuance, and FASB rules, we
were required to incur non-cash consulting expenses of $787,500 for the issuance
of these shares  during the  three-month  and  six-month  periods ended June 30,
2003.

NET  LOSS.  Net  operating  income  (less  Non-Cash  Consulting  Fees)  for  the
three-month  period  ended  June  30,2003  was  $322,623  and  $394,913  for the
six-month  period  ended  June  30,  2003.  When  Non-Cash  Consulting  Fees are
included,  the  Company had a net loss of $464,877  for the  three-month  period
ended June 30, 2003,  and a net loss of $392,587 for the six-month  period ended
June 30,  2003.  This  compares  to Net Income of $117,642  for the  three-month
period ended June 30, 2002, and net income of $305,102 for the six-month  period
ended June 30, 2002.



<PAGE>

ITEM 3.  CONTROLS AND PROCEDURES

We maintain controls and procedures designed to ensure that information required
to be  disclosed  in the  reports  that we file or submit  under the  Securities
Exchange Act of 1934 are recorded,  processed,  summarized,  and reported within
the time periods specified in the rules and forms of the Securities and Exchange
Commission.  Based  upon  their  evaluation  of those  controls  and  procedures
performed within 90 days of the filing date of this report,  our Chief Executive
and our Chief  Financial  Officer  concluded  that our  disclosure  controls and
procedures were adequate.

We made no significant changes in our internal controls or in other factors that
could  significantly  affect  these  controls  subsequent  to  the  date  of the
evaluations  of these  controls  by our Chief  Executive  Officer  and our Chief
Financial Officer.


                           PART II - OTHER INFORMATION

ITEM 1.  LEGAL PROCEEDINGS

On  June  3,  2003,  we  received  correspondence  from  counsel  to  an  entity
purportedly known as "Axiom  Pharmaceutical  Corporation," which alleged that we
were   infringing   upon  its  use  of  the  trademark   "Axiom   Pharmaceutical
Corporation."  We are  currently  investigating  this  allegation.  Although the
outcome of such investigation is currently unknown,  we do not believe that this
matter will have an adverse impact on our business or operations.

Other  than  as  disclosed  herein,  we are not a party  to any  material  legal
proceeding and no such proceeding is known to be contemplated.


ITEM 2.  CHANGES IN SECURITIES AND USE OF PROCEEDS

RECENT SALES OF UNREGISTED SECURITIES

On April  30,  2003,  we issued  30,000  shares of  restricted  Common  Stock to
Rabelaisian Resources,  Plc. pursuant to a consulting agreement. The shares were
issued pursuant to the exemption from  registration  provided by Section 4(2) of
the Securities Act of 1933, as amended (the "Securities Act."). The services are
to include business and product development.

On April 30, 2003, we issued 150,000 shares of restricted Common Stock to Madden
Consulting,  Inc.  pursuant to a  consulting  agreement.  The shares were issued
pursuant to the  exemption  from  registration  provided by Section  4(2) of the
Securities Act. The services provided are public relations consulting.

On May 1, 2003, we issued  25,000  shares of  restricted  Common Stock to Robert
Alexander pursuant to a consulting agreement. The shares were issued pursuant to
the exemption from registration  provided by Section 4(2) of the Securities Act.
The services  provided are  identification  and  consulting  for  acquisition of
pharmaceutical companies in Canada.

<PAGE>


On May 21, 2003, we issued  40,000  shares of restricted  Common Stock to Amaroq
Capital, LLC pursuant to a consulting agreement. The shares were issued pursuant
to the exemption  from  registration  provided by Section 4(2) of the Securities
Act. The services provided are business development and financial consulting.

On May 21, 2003, we issued 15,000 shares of restricted Common Stock to McCartney
Multimedia,  Inc.  pursuant to a  consulting  agreement.  The shares were issued
pursuant to the  exemption  from  registration  provided by Section  4(2) of the
Securities Act. The services provided are the creation of company's web site and
logo.

On June 27,  2003,  we  issued  80,000  shares  of  restricted  Common  Stock to
Woodbridge Management,  Ltd. pursuant to a consulting agreement. The shares were
issued pursuant to the exemption from  registration  provided by Section 4(2) of
the Securities Act. The services provided are financial consulting.


ITEM 3.  DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

Not applicable.

ITEM 5. OTHER INFORMATION

Not applicable.

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K

(a) The following exhibits are filed as part of this report.

           Exhibit No.                     Document

           31.1  Certification  of  Chief  Executive  Officer  required  by Rule
                 13a-14/15d-14(a) under the Exchange Act.

           31.2  Certification  of  Chief  Financial  Officer  required  by Rule
                 13a-14/15d-14(a) under the Exchange Act.

           32.1  Certification of Chief Executive  Officer pursuant to 18 U.S.C.
                 Section 1350, as adopted  pursuant   to  Section   906  of  the
                 Sarbanes-Oxley Act of 2002.

           32.2  Certification of Chief Financial  Officer pursuant to 18 U.S.C.
                 Section 1350, as adopted  pursuant   to  Section   906  of  the
                 Sarbanes-Oxley Act of 2002.

<PAGE>


(b) Reports of Form 8-K

We filed the  following  Current  Reports on Form 8-K during the  quarter  ended
March 31, 2003:

On May 29, 2003,  we filed an  amendment on Form 8-K/A to our Current  Report on
Form 8-K,  originally filed on March 21, 2003. The amendment  included financial
statements regarding our acquisition of Werke  Pharmaceuticals,  Inc. On July 1,
2003, we filed an additional amendment on Form 8-K/A in order to correct certain
disclosures regarding beneficial ownership of our officers,  directors and 5% or
greater shareholders.


                                   SIGNATURES

In accordance with the  requirements of the Exchange Act, the registrant  caused
this  report to be  signed on its  behalf  by the  undersigned,  thereunto  duly
authorized.


Date:  August 13, 2003                      AXIOM PHARMACEUTICALS, INC.

                                            By:   /s/ That Ngo
                                                      ------------------------
                                                      That Ngo, President
                                                 /s/  Xian Fen Guo
                                                      ------------------------
                                                      Xian Fen Guo,
                                                      Chief Financial Officer